Nektar Therapeutics held its Annual Meeting of Stockholders on May 23, 2025. During the meeting, several proposals were addressed. The election of Diana Brainard and R. Scott Greer to the board of directors was approved. An amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance by 6,000,000 shares was approved. An amendment to the Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 to 390,000,000 shares was approved. Additionally, an amendment to the Certificate of Incorporation to effect a reverse stock split of common stock at a ratio between 1-for-2 and 1-for-40, at the discretion of the Board, was approved.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。